CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. Its business is to act as a full-service, non-clinical global drug-development partner, providing research-model technologies, GLP and non-GLP discovery and safety-assessment services, and manufacturing-support products. In 2025, total revenue was $4.0 billion, split 21.1% Research Models and Services (RMS), 59.8% Discovery and Safety Assessment (DSA), and 19.1% Manufacturing Solutions. The company runs more than 120 sites across more than 20 countries.

The commercial story is one of breadth and scale rather than current profitability strength. DSA accounts for nearly three-fifths of revenue, Charles River occupies a specialist outsourced role between basic research and human clinical trials, and the global footprint gives it multi-country client access. However, the financial returns do not show a durable pricing moat today. The trailing net margin is -6.0%, return on equity is -7.7%, and the P/E ratio is negative at -62.4. Those figures mean the company is currently losing money and eroding shareholders’ equity on a trailing basis, which is consistent with a turnaround or restructuring story rather than a wide-moat, high-return compounder.

Financial posture

With a $14.5 billion market cap and a current price of $301.86, Charles River trades at a negative P/E of -62.4 because reported earnings over the relevant period have been negative. The -6.0% net margin and -7.7% ROE confirm that valuation cannot be anchored to trailing profitability. The stock sits above its 50-day exponential moving average of $278.50, and the RSI is 59.0, a neutral-to-firm momentum reading rather than an extreme overbought level.

The share price has risen 75.8% over the past year, according to an October 7, 2026 Zacks headline, even though the headline margin and return metrics are negative. That divergence suggests the market is pricing in a recovery in non-clinical CRO demand, the benefits of cost restructuring, or eventual margin normalization rather than current earnings power. The beta is 1.40, indicating the stock has historically moved about 40% more than the broader market, which fits an economically sensitive, discretionary services business tied to biopharma R&D spending.

Strategic priorities & outlook

The company’s most recent 10-K summarizes a near-term agenda built on footprint rationalization, organizational integration, and biologics expansion. Management plans to close or consolidate approximately 12 additional sites over the next two years, principally within DSA and RMS. It is also merging Discovery Services and Safety Assessment into a single DSA organization with a combined sales force and leadership structure. The stated objective is to become the scientific partner of choice by offering a comprehensive, integrated portfolio intended to speed biomedical research and therapeutic innovation. In parallel, the company intends to keep expanding Biologics Testing Solutions service offerings and facilities in the U.S. and Europe.

A concrete recent step came in January 2026 with the acquisition of certain assets of K.F. (Cambodia) Ltd., a supplier of non-human primates. That deal is meant to support DSA supply operations and RMS third-party sales. Because DSA represented 59.8% of 2025 revenue, securing research-model supply is strategically important, even as the site-consolidation program tries to lower structural overhead.

Macro & geopolitical exposure

As a Healthcare / Medical Diagnostics & Research services provider, Charles River’s biggest macro variable is biopharmaceutical R&D spending. When biotechnology funding is abundant and large pharmaceutical pipelines are active, demand for outsourced non-clinical testing tends to rise; when capital tightens, discovery and safety-assessment budgets are among the first areas to face scrutiny. Interest rates and capital-market conditions for biotech issuers are therefore indirect demand drivers.

Regulatory exposure is also significant. The FDA, EMA, and other health authorities set GLP, animal-welfare, and facility-approval standards that directly affect how studies are conducted. Rules governing the import and use of non-human primates can influence supply availability and cost, as can wildlife-trade and export restrictions in source countries such as Cambodia. Foreign-currency translation matters because the company operates across more than 20 countries. Tariffs or logistics disruptions on research models, specialized reagents, and laboratory equipment can flow through margins. Finally, the growth of biologics and advanced therapies creates demand for Biologics Testing Solutions, but also attracts competition from specialized CROs and in-house capabilities at large pharmaceutical companies.

Recent developments

On October 9, 2026, businesswire.com reported that Charles River scheduled its third-quarter 2026 earnings release and conference call. That event feeds into the next scheduled report on November 4, 2026, before the market open, for which the current consensus EPS estimate is $2.97. On October 7, 2026, Zacks published a comparison asking whether Progyny (PGNY) or CRL is the better value stock right now, signaling that valuation debates are active among healthcare services names. The same day, Zacks also highlighted that Charles River had gained 75.8% in a year and examined what has been driving the rally. On October 6, 2026, businesswire.com announced a partnership between Charles River and Autolomous to transform laboratory execution systems, a move that could improve data workflow and operational efficiency.

Taken together, these items portray a company in transition: the stock has rallied sharply, operational partnerships are being announced, and the upcoming quarterly report will be a near-term catalyst. The market’s real expectation appears to be that management can convert restructuring actions into improved margins while continuing its long streak of beating published earnings estimates.

Earnings behavior & post-earnings drift

Charles River has beaten earnings estimates in all of the last eight reported quarters, for a 100% beat rate, with an average earnings surprise of 9.3%. Across those reports, the average five-day post-earnings price move has been +1.24%, classified as an upward post-earnings drift.

The last four quarters show that beats do not always produce uniformly positive price reactions. On August 5, 2026, the company reported EPS of $3.02 versus a $2.74 estimate, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five trading days. On May 7, 2026, actual EPS of $2.06 beat the $1.96 estimate by 5.1%, yet the stock fell 2.23% the next session and 12.42% over the next five days. On February 18, 2026, a $2.39 print against a $2.33 estimate, a 2.6% beat, produced a 3.95% next-day gain and a 6.05% five-day gain. On November 5, 2025, $2.43 versus $2.32, a 4.7% beat, resulted in a 1.9% next-day move and a 2.27% five-day move.

The pattern is consistent on the headline—every report cleared consensus—but the post-earnings drift has varied materially. The November 4, 2026 report, with a current consensus EPS estimate of $2.97, will test whether the 100% beat streak continues and whether the average upward post-earnings drift reasserts after the mixed May 2026 reaction.

For a deeper dive into how institutional analysts are interpreting these fundamentals, valuation metrics, and upcoming catalysts, explore the full institutional verdict on CRL.